Momenta develops or was developing biosimilar FSH (see here below abstract of a new article).
I don’t think MNTA has any interest in FSH per se; rather, FSH is mentioned in the paper you cited as an example to illustrate MNTA’s purification process. From your post:
Here, we use recombinant human follicle stimulating hormone…from a pharmaceutical source as an example to illustrate a suitable purification strategy to effectively extract the bulk drug substance from the formulated drug product with high purity and yield.
Regards, Dew
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”